Jasper Therapeutics, Inc.

JSPR Nasdaq SEC CIK 1788028
Follow Jasper Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $8M
Net income −$144.5M −671% vs same quarter last year
EPS, diluted −$10.19 +68.2% vs same quarter last year
Operating cash flow −$5.5M +67.7% vs same quarter last year
Net income by quarter
−$24.4M
−$21.2M
−$26.7M
−$18.7M
$66.7M
−$1.2M
−$2.8M
−$144.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$75.8
FY24−$71.3M
FY23−$64.5M
FY22−$37.7M
FY21−$30.6M
FY20−$31.7M
FY19-